

(19) World Intellectual Property Organization
International Bureau



506, 721
10/506721
Rec'd PCT/PTO 07 SEP 2004

(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076418 A1

(51) International Patent Classification⁷: C07D 239/91,
239/90, 413/12, 409/12, A61K 31/517, A61P 35/00

(21) International Application Number: PCT/US03/06793

(22) International Filing Date: 4 March 2003 (04.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/363,132 7 March 2002 (07.03.2002) US

(71) Applicant (for all designated States except US): X-CEP-
TOR THERAPEUTICS, INC. [US/US]; 4757 Nexus
Centre Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MARTIN, Richard
[CA/US]; 4293 Cordobes Cove, San Diego, CA 92130
(US). KAHL, Jeffery, Dean [US/US]; 10502 Jepson
Lane, San Diego, CA 92131 (US). FLATT, Brenton,
Todd [US/US]; 12721 Pedriza Drive, Poway, CA 92064
(US). GRIFFITH, Ronald [US/US]; 2508 Russett Glen,
Escondido, CA 92029 (US).

(74) Agents: ROTH, Carol, J. et al.; Seed Intellectual Property
Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle,
WA 98104-7092 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS

(57) Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided.
In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

WO 03/076418 A1